NICE backs NHS use of Novartis’ cholesterol drug LeqvioNovartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help Share XNICE backs NHS use of Novartis’ cholesterol drug Leqviohttps://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/
Novartis eyes New Year verdict from FDA on delayed LeqvioNovartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by Share XNovartis eyes New Year verdict from FDA on delayed Leqviohttps://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/
Novartis tries to rescue stalled inclisiran filing with FDANovartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on Share XNovartis tries to rescue stalled inclisiran filing with FDAhttps://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
AstraZeneca sells rights to cholesterol drug Crestor to GrunenthalAstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a Share XAstraZeneca sells rights to cholesterol drug Crestor to Grunenthalhttps://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
AZ buys oral PCSK9 cholesterol drug from Dogma TherapeuticsAstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share XAZ buys oral PCSK9 cholesterol drug from Dogma Therapeuticshttps://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
